logo
logo

Elektrofi Raises $40 Million Financing To Establish Gmp Manufacturing Capabilities For Upcoming Clinical Studies And Expand Development Pipeline

Jun 13, 2022•about 3 years ago

Amount Raised

$40 Million

Boston

Description

Elektrofi, a Boston-based biotechnology company focused on drug formulation and delivery innovations, today announced the completion of a $40 million Series B financing round. A portion of the proceeds will be used to establish a centralized GMP manufacturing line in support of multiple upcoming clinical trials. The company will also plan to double headcount over the next 12-18 months to accelerate development across a growing pipeline of licensed programs with leading pharma and biotech.

Company Information

Company

Elektrofi

Location

Boston, Massachusetts, United States

About

Elektrofi is a biotechnology company focused on improving administration for a wide range of medicines including monoclonal antibodies, therapeutic proteins, and other large molecule drugs. Its breakthrough formulation platform enables stabilized, highly concentrated formulations for subcutaneous administration. The company is using this technology to transform therapies that are administered intravenously, and to enhance injectable products by reducing the volume and frequency of dosing. Elektrofi partners with pharmaceutical companies to jointly develop patient-friendly delivery solutions. Headquartered in Boston, the company is shaping the future of biologics delivery. Visit www.elektrofi.com for more information.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech